FDA D.I.S.C.O. Burst Edition: FDA approval of Lenvima (lenvatinib) in combination with Keytruda (pembrolizumab) for first-line treatment of adult patients with advanced renal cell carcinoma
0:00
3:30
Listen to a soundcast of the August 10, 2021 FDA approval of Lenvima (lenvatinib) in combination with Keytruda (pembrolizumab) for first-line treatment of adult patients with advanced renal cell carcinoma
Mais episódios de "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Não percas um episódio de “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” e subscrevê-lo na aplicação GetPodcast.